These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 19874362)

  • 1. Photochemotherapy for systemic sclerosis: effect on clinical and molecular markers.
    Usmani N; Murphy A; Veale D; Goulden V; Goodfield M
    Clin Exp Dermatol; 2010 Aug; 35(6):608-13. PubMed ID: 19874362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photochemotherapy for localized morphoea: effect on clinical and molecular markers.
    Usmani N; Murphy A; Veale D; Goulden V; Goodfield M
    Clin Exp Dermatol; 2008 Nov; 33(6):698-704. PubMed ID: 18699840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
    Yanaba K; Komura K; Kodera M; Matsushita T; Hasegawa M; Takehara K; Sato S
    Ann Rheum Dis; 2006 Jan; 65(1):124-6. PubMed ID: 16344498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis.
    Jinnin M; Makino T; Kajihara I; Honda N; Makino K; Ogata A; Ihn H
    Br J Dermatol; 2010 Apr; 162(4):751-8. PubMed ID: 19886888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostacyclin analogue iloprost influences endothelial cell-associated soluble adhesion molecules and growth factors in patients with systemic sclerosis: a time course study of serum concentrations.
    Rehberger P; Beckheinrich-Mrowka P; Haustein UF; Sticherling M
    Acta Derm Venereol; 2009; 89(3):245-9. PubMed ID: 19479119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity.
    Yoshizaki A; Iwata Y; Komura K; Hara T; Ogawa F; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2008 Sep; 35(9):1825-9. PubMed ID: 18688912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phototherapy: a promising treatment option for skin sclerosis in scleroderma?
    Sunderkötter C; Kuhn A; Hunzelmann N; Beissert S
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii52-iii54. PubMed ID: 16987838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis.
    Genovese MC; Chakravarty EF; Boyle DL; Tutuncu Z; Thorburn CM; Halilhodzic M; Kroll S; Baughman J; Stewart S; Kavanaugh A
    J Rheumatol; 2005 Dec; 32(12):2345-50. PubMed ID: 16331761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Plasmapheresis therapy in systemic sclerosis].
    Szúcs G; Szamosi S; Aleksza M; Veres K; Soltész P
    Orv Hetil; 2003 Nov; 144(45):2213-7. PubMed ID: 14686006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.
    Apras S; Ertenli I; Ozbalkan Z; Kiraz S; Ozturk MA; Haznedaroglu IC; Cobankara V; Pay S; Calguneri M
    Arthritis Rheum; 2003 Aug; 48(8):2256-61. PubMed ID: 12905480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two cases of cutaneous chronic graft versus host disease in treatment with psoralen plus ultraviolet-A-bath photochemotherapy.
    Hoffner MV; Carrizosa Esquivel A; Pulpillo Ruiz A; Herrera Saval A; Conejo-Mir J; Camacho FM
    J Drugs Dermatol; 2009 Nov; 8(11):1027-9. PubMed ID: 19894371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?
    Carulli MT; Handler C; Coghlan JG; Black CM; Denton CP
    Ann Rheum Dis; 2008 Jan; 67(1):105-9. PubMed ID: 17604287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interleukin-2 and interleukin-6 in serum as markers of disease progression in systemic sclerosis].
    Lis A; Brzezińska-Wcisło L
    Pol Merkur Lekarski; 2001 Sep; 11(63):206-9. PubMed ID: 11761811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cartilage oligomeric matrix protein in systemic sclerosis.
    Yamamoto M; Takahashi H; Suzuki C; Naishiro Y; Yamamoto H; Imai K; Shinomura Y
    Rheumatology (Oxford); 2007 Dec; 46(12):1858-9. PubMed ID: 17895282
    [No Abstract]   [Full Text] [Related]  

  • 15. Construct validity evaluation of the European Scleroderma Study Group activity index, and investigation of possible new disease activity markers in systemic sclerosis.
    Minier T; Nagy Z; Bálint Z; Farkas H; Radics J; Kumánovics G; Czömpöly T; Simon D; Varjú C; Németh P; Czirják L
    Rheumatology (Oxford); 2010 Jun; 49(6):1133-45. PubMed ID: 20236952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between occupational risk factors and severity markers of systemic sclerosis.
    Magnant J; de Monte M; Guilmot JL; Lasfargues G; Diot P; Asquier E; Degenne D; Boissinot E; Diot E
    J Rheumatol; 2005 Sep; 32(9):1713-8. PubMed ID: 16142866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.
    Yanaba K; Muroi E; Yoshizaki A; Hara T; Ogawa F; Shimizu K; Yozaki M; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 Sep; 36(9):1917-23. PubMed ID: 19605674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Soluble receptors of cytokines in sera of patients with systemic sclerosis--clinical correlation].
    Lis AD; Brzezińska-Wcisło LA
    Wiad Lek; 2003; 56(11-12):532-6. PubMed ID: 15058159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil.
    Clements PJ; Peter JB; Agopian MS; Telian NS; Furst DE
    J Rheumatol; 1990 Jul; 17(7):908-10. PubMed ID: 2213757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.